News Medical on MSN
Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes
While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
Elana Thieme and Mark Mendoza, fourth-year graduate students in the Molecular and Cell Biology (MCB) PhD Program jointly administered by Fred Hutch Cancer Center and the University of Washington, have ...
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback